- Home
- SGRP vs QNCX Comparison
SGRP vs QNCX Comparison
Compare SGRP & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGRP | QNCX |
|---|---|---|
| Founded | 1967 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 19.9M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SGRP | QNCX |
|---|---|---|
| Price | $0.85 | $17.70 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.9K | ★ 261.0K |
| Earning Date | 03-31-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $136,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.08 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.08 |
| 52 Week High | $1.41 | $19.26 |
Technical Indicators
Market Signals| Indicator | SGRP | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 89.81 |
| Support Level | $0.74 | $0.89 |
| Resistance Level | $0.82 | $19.26 |
| Average True Range (ATR) | 0.06 | 0.74 |
| MACD | -0.01 | 1.75 |
| Stochastic Oscillator | 58.95 | 90.42 |
Price Performance
Historical ComparisonAbout SGRP SPAR Group Inc.
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. The company provides five principal types of services: Merchandising, Marketing and Category Management, Remodel and Retail Transformation, Assembly and Installation, Fulfilment and Distribution, and Business Analytics and Insights. It operates in two segments, namely the U.S. and Canada, with the majority of the revenues deriving from the U.S. segment.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.